Drug Utilization Review (DUR) Software: What Every Pharmacy Should Automate

Introduction

Drug Utilization Review has always mattered. What has changed is that doing it manually has become operationally untenable. Dispensing volumes keep climbing. Drug interaction databases keep expanding. And regulatory expectations around documentation keep tightening. The gap between what thorough DUR actually requires and what a pharmacy team can realistically accomplish without automation is not a gap anymore — it is a chasm.

DUR software closes that gap by turning what was a time-intensive manual process into an automated safety and compliance layer that runs quietly in the background of every dispensing transaction. PharmaWize is built to embed DUR checks directly into the dispensing workflow — catching issues before they ever reach the patient.

Think about what manual DUR actually demands at a pharmacy processing several hundred prescriptions a day. A pharmacist would need to cross-reference every new prescription against a patient’s complete medication history, across an interaction database that changes constantly, for every single transaction. The knowledge required is enormous. The margin for error is unacceptable. And the consequences of missing something are serious in a way that most operational errors simply are not.

Three Types of DUR

Prospective DUR

This is the most familiar form — review before dispensing. Prospective DUR checks happen at the point of processing and cover drug-drug interaction screening, allergy cross-checks, therapeutic duplication alerts, dose range validation, and formulary appropriateness. This is where automation delivers its most immediate patient safety benefit, and where the case for a purpose-built pharmacy clinical decision support system is hardest to argue against.

Retrospective DUR

Performed after dispensing, retrospective DUR looks at patterns across a patient population rather than individual transactions. It surfaces things like chronic overuse, prescribing patterns that deviate from clinical guidelines, or patient groups with elevated adverse event risk. Less visible than prospective DUR, but genuinely valuable for quality improvement programs and payer reporting.

Concurrent DUR

Concurrent review happens during ongoing therapy — monitoring adherence, therapy duration limits, and lab monitoring requirements for patients on long-term medications. It is particularly relevant for anything requiring regular therapeutic drug monitoring, where a single snapshot at dispensing is not enough to manage clinical risk over time.

What Automated DUR Alerts Should Cover

A properly configured DUR system should be doing more than flagging obvious interactions. A complete pharmacy clinical decision support setup generates alerts for:

Drug-drug interactions — cross-referencing every new prescription against all active medications, with severity ratings and specific clinical recommendations attached
Therapeutic duplication — flagging two medications from the same class, which is especially important in multi-prescriber environments where no single prescriber has the full picture
Dose range checks — validating against age-appropriate and indication-appropriate ranges, not just generic adult dosing
Allergy and adverse reaction cross-checks — including cross-sensitivity warnings for related drug classes, not just the specific allergen on file
Duration of therapy alerts — flagging prescriptions that exceed typical treatment lengths for antibiotics, controlled substances, and corticosteroids
Age and condition contraindications — automated drug interaction alerts need to include population-specific checks, not just a one-size-fits-all screen

If your current system is only catching the obvious drug-drug interactions and leaving everything else to manual review, it is doing less than half the job.

How DUR Data Feeds Audit Readiness

One of the underappreciated benefits of automated DUR is what it produces as a byproduct of normal operations — a complete, timestamped documentation trail that does not require anyone to go back and reconstruct it later.

Every alert is logged with timestamps and the pharmacist’s response. Override reasons are captured in structured fields. Response times are tracked. And aggregate data compiles into regulatory reports without someone having to manually gather it when an audit notice arrives.

WizeAI can layer analytics on top of that DUR data, identifying patterns in alert types, override rates, and prescriber-specific trends that help pharmacy managers focus quality improvement where it is actually needed — rather than treating every override the same way.

Connecting DUR to Patient Counseling

Automation does not replace the pharmacist. What it does is equip the pharmacist with better information at the exact moment it matters most.

When a DUR alert flags a clinically significant interaction, the pharmacist walks into that counseling conversation with a specific, evidence-based concern to communicate — not a vague sense that something might be worth mentioning. The software handles the computational burden of cross-referencing thousands of possible interactions across a patient’s full medication history. The pharmacist brings the clinical judgment and communication skills that no algorithm is going to replicate.

Done right, DUR automation makes pharmacist counseling sharper and more credible. It does not make it optional.

Common Mistakes When Implementing DUR Software

Setting alert sensitivity too high. Too many low-severity alerts train pharmacists to override warnings without actually reviewing them. This is how alert fatigue develops, and it is how the system stops providing real safety value. Calibrate severity levels carefully and track override rates from day one.
Not customizing to your patient population. A geriatric-focused pharmacy has completely different DUR priorities than a pediatric one. Default configurations are built for a generic patient population. They may not match yours at all. Review defaults before go-live and adjust them.
Failing to train staff on response protocols. Software flags the issue. Staff need to know what to do with that flag — when to override, when to consult the prescriber, and when to counsel the patient. Clear protocols are not optional.
Treating DUR as only a compliance requirement. DUR data can inform purchasing decisions, identify high-risk patients for Medication Therapy Management services, and genuinely strengthen a pharmacy’s clinical reputation. Facilities that treat it as nothing more than a regulatory checkbox are leaving real value on the table.
Not connecting DUR data to patient profiles. A patient who has triggered three significant interaction alerts in six months is telling you something. That pattern should be prompting a comprehensive medication review — not just three separate override notes.

Quick Checklist: Evaluating DUR Software

Supports prospective, retrospective, and concurrent DUR?
Drug interaction databases updated automatically on a regular schedule?
Alert severity levels configurable to your patient population?
Structured override reasons captured for audit trails?
DUR alerts integrated directly into the dispensing queue?
Aggregate DUR reports generated for regulatory submission?
Pharmacist response times and override rates tracked?

Where This Fits in the WizeHealth Ecosystem

DUR is fundamentally a clinical function, but its data reaches well beyond clinical decisions.

Interaction alerts affect dispensing throughput. Override patterns reveal training gaps. And DUR data can identify patients who would genuinely benefit from additional clinical services if anyone is paying attention to it.

Within the WizeHealth ecosystem, PharmaWize embeds DUR checks directly into the dispensing workflow. WizeAI adds the analytics layer — surfacing patterns in alert trends, override rates, and prescriber-specific issues that would be invisible in raw DUR logs.

WizeCompli connects DUR documentation to the broader compliance framework, so nothing gets siloed.

FAQ

Most reputable systems update at least monthly, with some providing weekly or daily updates for critical safety information. Update frequency is worth asking about specifically when you are evaluating vendors — the answer tells you a lot about how seriously they treat the clinical side of their product.

Alert fatigue is what happens when too many low-severity alerts train pharmacists to click through warnings without reviewing them carefully. Well-designed software addresses this through configurable severity tiers — suppressing genuinely low-risk alerts while requiring documented review for anything clinically significant. The goal is fewer alerts that actually get read, not more alerts that get ignored.

That depends on how complete the patient profile is. Systems integrated with prescription drug monitoring programs (PDMPs) or shared health records can access broader medication histories. A patient who fills controlled substances at three different pharmacies is exactly the kind of case where that integration matters most.

When properly integrated, clinical checks happen at both the prescriber level and the pharmacy level. This double-check catches things that either system alone might miss — particularly important given how many prescribers are working across multiple patients and may not have a patient’s complete pharmacy history in front of them.

In the U.S., OBRA-90 mandates prospective DUR for Medicaid prescriptions, and most state pharmacy boards extend similar requirements to all prescriptions. Canadian provinces have analogous requirements. But regardless of what the mandate says, DUR is a professional standard of practice — the legal requirement is almost beside the point.